MipitrobanAlternative Names: UP 11677
Latest Information Update: 21 Nov 2007
At a glance
- Originator UPSA
- Class Antiplatelets
- Mechanism of Action Thromboxane A2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 02 Sep 1997 UP 11677 is now called mipitroban
- 29 Mar 1996 No-Development-Reported for Thrombosis in USA (Unknown route)
- 29 Mar 1996 No-Development-Reported for Thrombosis in France (Unknown route)